Systemic lupus erythematosus: review of synthetic drugs

@article{TsangASjoe2015SystemicLE,
  title={Systemic lupus erythematosus: review of synthetic drugs},
  author={M. Tsang-A-Sjoe and I. Bultink},
  journal={Expert Opinion on Pharmacotherapy},
  year={2015},
  volume={16},
  pages={2793 - 2806}
}
  • M. Tsang-A-Sjoe, I. Bultink
  • Published 2015
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Introduction: Synthetic drugs are prescribed for nearly all patients with systemic lupus erythematosus (SLE), a multisystem autoimmune disease, to ameliorate symptoms and positively influence outcome. While only 2 biologic agents have been approved for the treatment of SLE, synthetic drugs are still the mainstay of therapy in SLE. The highly variable and unpredictable course of SLE poses a challenge for physicians as to what drug(s) should be prescribed for which patient. Areas covered… CONTINUE READING
    15 Citations
    Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review
    • 3
    The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation
    • 2
    • PDF
    Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.
    • 2
    • PDF

    References

    SHOWING 1-10 OF 134 REFERENCES
    Systemic lupus erythematosus
    • 558
    A 2 year, open ended trial of methotrexate in systemic lupus erythematosus.
    • 41
    Trends in the outpatient medication management of lupus erythematosus in the United States.
    • 6